Subscribe to Newsletter
U2XLab develops and validates methods optimized for every stage of drug development,
With a specialized focus on highly complex domains.
Delivering globally compliant data and enhanced clinical insights
By integrating LC-MS/MS and immunoassay platforms with our RVDS-based IT infrastructure.

Delivering customized analytical strategies optimized for each drug candidate's specific profile, utilizing a diverse suite of platforms such as LC‑MS/MS, immunoassays, flow cytometry, and qPCR

Offering a comprehensive analytical portfolio dedicated to clinical trials, including PK/PD, ADA, biomarker analysis, and PBMC isolation

Establishing tailored analytical methods that reflect the unique profiles of biomarkers across major therapeutic areas, including Oncology, Immunology, and CNS.
U2XLab is a GCLP-certified laboratory that pioneered South Korea's first Central Lab services for clinical trials across Asia. Since our founding in 2012, we have supported the entire clinical trial lifecycle through analytical services and quality management that meet global standards.
U2XLab at KIC 2026: Event Recap
U2XLab Attends BIO JAPAN 2026 to Explore Global Business Opportunities
[The Chosun Daily] 100% Tuition Support for Employees’ Children, Regardless of the Number of Children
NEWSLETTER 2026.3Q
Meet U2XLab at KIC 2026! 🔬